Evidence map›Paper›PMID 27412679›Full record

ArticleInternational urology and nephrology2016

Oxidative stress and hemoglobin-cholesterol adduct in renal patients with different LDL phenotypes.

Milica Miljkovic, Jelena Kotur-Stevuljevic, Aleksandra Stefanovic, Aleksandra Zeljkovic, Jelena Vekic, Tamara Gojkovic, Natasa Bogavac-Stanojevic, Milan Nikolic, Sanja Simic-Ogrizovic, Vesna Spasojevic-Kalimanovska and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in International urology and nephrology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 94% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Milica MiljkovicDepartment of Medical Biochemistry, Faculty of Pharmacy, University of Belgrade, Vojvode Stepe 450, P. Box 146, 11000, Belgrade, Serbia. milicammiljkovic@gmail.com.
Jelena Kotur-StevuljevicDepartment of Medical Biochemistry, Faculty of Pharmacy, University of Belgrade, Vojvode Stepe 450, P. Box 146, 11000, Belgrade, Serbia.
Aleksandra StefanovicDepartment of Medical Biochemistry, Faculty of Pharmacy, University of Belgrade, Vojvode Stepe 450, P. Box 146, 11000, Belgrade, Serbia.
Aleksandra ZeljkovicDepartment of Medical Biochemistry, Faculty of Pharmacy, University of Belgrade, Vojvode Stepe 450, P. Box 146, 11000, Belgrade, Serbia.
Jelena VekicDepartment of Medical Biochemistry, Faculty of Pharmacy, University of Belgrade, Vojvode Stepe 450, P. Box 146, 11000, Belgrade, Serbia.
Tamara GojkovicDepartment of Medical Biochemistry, Faculty of Pharmacy, University of Belgrade, Vojvode Stepe 450, P. Box 146, 11000, Belgrade, Serbia.
Natasa Bogavac-StanojevicDepartment of Medical Biochemistry, Faculty of Pharmacy, University of Belgrade, Vojvode Stepe 450, P. Box 146, 11000, Belgrade, Serbia.
Milan NikolicDepartment of Biochemistry, Faculty of Chemistry, University of Belgrade, Studentski trg 16, 11000, Belgrade, Serbia.
Sanja Simic-OgrizovicClinic of Nephrology, Clinical Center of Serbia, Pasterova 2, 11000, Belgrade, Serbia.
Vesna Spasojevic-KalimanovskaDepartment of Medical Biochemistry, Faculty of Pharmacy, University of Belgrade, Vojvode Stepe 450, P. Box 146, 11000, Belgrade, Serbia.
Zorana Jelic-IvanovicDepartment of Medical Biochemistry, Faculty of Pharmacy, University of Belgrade, Vojvode Stepe 450, P. Box 146, 11000, Belgrade, Serbia.
University of Belgrade · RS

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeUnfavorable lipid profile is a major risk factor for cardiovascular disease in renal pathology. In this study, we compared chronic renal patients and healthy controls with different LDL phenotypes (A or B) in respect of various biochemical parameters related to cardiovascular disease.

methodsOxidative stress and anti-oxidative defense parameters [thiobarbituric acid-reacting substances (TBARS), total oxidative status (TOS), total anti-oxidative status (TAS), total protein sulfhydryl (-SH) groups], as well as red blood cell cholesterol distribution were assessed in 40 renal patients and 40 control subjects by standardized assays. LDL particle diameters were determined by polyacrylamide gradient gel electrophoresis. LDL particles are subdivided according to their size into large LDL A phenotype (diameter >25.5 nm) and small LDL B phenotype (diameter ≤25.5 nm).

resultsRenal patients with LDL A phenotype had increased oxidative stress (TOS: p < 0.01, and TBARS: p < 0.001) and decreased total SH- groups (p < 0.001) compared to controls with the same LDL phenotype. A notable decrease in hemoglobin-cholesterol adduct was detected in patients with LDL A phenotype (p < 0.001) and LDL B phenotype (p < 0.05) compared with appropriate controls. LDL B phenotype was characterized with increased TBARS (p < 0.05) compared with LDL A phenotype in control group.

conclusionIncreased oxidative stress, decreased anti-oxidative defense followed with unfavorable changes in hemoglobin-cholesterol binding capacity, could have important influence on cardiovascular disease risk in renal patients regardless of LDL phenotype.

Indexed as

Cholesterol, LDLHemoglobinsRenal Insufficiency, ChronicAdaptor Proteins, Vesicular TransportAdultAgedCardiovascular DiseasesErythrocyte MembraneFemaleHumansMaleMiddle AgedOxidative StressPhenotypeRisk FactorsStatistics as TopicAdaptor Proteins, Vesicular TransportCholesterol, LDLCOG1 protein, humanHemoglobinsThiobarbituric Acid Reactive SubstancesAnti-oxidative defenseHemoglobin–cholesterol adductLDL particlesOxidative stressRed blood cell membrane cholesterol

Identifiers

PMID27412679
OpenAlexW2470623430

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.